Find Quizartinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 950769-58-1, Ac220, Quizartinib (ac220), Ac-220, Ac 220, Quizartinib hcl
Molecular Formula
C29H32N6O4S
Molecular Weight
560.7  g/mol
InChI Key
CVWXJKQAOSCOAB-UHFFFAOYSA-N
FDA UNII
7LA4O6Q0D3

Quizartinib
Quizartinib is an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.
1 2D Structure

Quizartinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea
2.1.2 InChI
InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
2.1.3 InChI Key
CVWXJKQAOSCOAB-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3
2.2 Other Identifiers
2.2.1 UNII
7LA4O6Q0D3
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Ac220 Compound

2.3.2 Depositor-Supplied Synonyms

1. 950769-58-1

2. Ac220

3. Quizartinib (ac220)

4. Ac-220

5. Ac 220

6. Quizartinib Hcl

7. Ac010220

8. Quizartinib Freebase

9. Ac 010220

10. Asp-2689

11. 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea

12. 7la4o6q0d3

13. Chembl576982

14. N-(5-tert-butylisoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea

15. Chebi:90217

16. 950769-58-1 (free Base)

17. Ac-010220

18. 1132827-21-4 (hcl)

19. 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-{7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea

20. 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea

21. N-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride

22. Chembl2386811

23. 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)-benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea

24. N-(5-(1,1-dimethylethyl)isoxazol-3-yl)-n'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1- B)benzothiazol-2-yl)phenyl)urea

25. N-(5-(1,1-dimethylethyl)isoxazol-3-yl)-n'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)urea

26. Urea, N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-n'-(4-(7-(2-(4-morpholinyl)ethoxy) Imidazo(2,1-b)benzothiazol-2-yl)phenyl)-

27. Ac220 Compound

28. Ac220,quizartinib

29. Quizartinib [usan]

30. Quizartinib [usan:inn]

31. Quizartinibum

32. Unii-7la4o6q0d3

33. 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)(1,3)benzothiazol-2-yl)phenyl)urea

34. N-(5-tert-butylisoxazol-3-yl)-n'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)(1,3)benzothiazol-2-yl)phenyl)urea

35. N-(5-tert-butylisoxazol-3-yl)-n'-[4-[7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea

36. Quizartinib, 95%

37. Quizartinib, Ac220

38. Quizartinib, Free Base

39. Ac220 - Quizartinib

40. Quizartinib [mi]

41. Quizartinib; Plx3397

42. Quizartinib [inn]

43. Quizartinib (usan/inn)

44. Quizartinib, Ac010220

45. Schembl72923

46. Quizartinib [who-dd]

47. Mls006011240

48. Gtpl5658

49. Dtxsid70241746

50. Bcpp000443

51. Hms3244k09

52. Hms3244k10

53. Hms3244l09

54. Hms3265g09

55. Hms3265g10

56. Hms3265h09

57. Hms3265h10

58. Hms3654j20

59. Hms3743g21

60. Bcp02224

61. Bdbm50300690

62. Mfcd18074524

63. Nsc756647

64. Nsc799659

65. Nsc800857

66. S1526

67. Zinc43204002

68. Akos015891557

69. Bcp9000223

70. Ccg-264906

71. Cs-0211

72. Db12874

73. Nsc-756647

74. Nsc-799659

75. Nsc-800857

76. Sb16610

77. Ncgc00242493-01

78. Ncgc00242493-02

79. Ncgc00242493-07

80. As-16178

81. Hy-13001

82. Smr004703000

83. Ft-0687630

84. Sw218131-2

85. D09955

86. J-524214

87. Q7272714

88. Brd-k93918653-001-01-4

89. 3-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4-{10-[2-(morpholin-4-yl)ethoxy]-7-thia-2,5-diazatricyclo[6.4.0.0^{2,6}]dodeca-1(12),3,5,8,10-pentaen-4-yl}phenyl)urea

90. N-(5-tert-butyl-isoxazol-3-yl)-n''-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea

91. N-(5-tert-butyl-isoxazol-3-yl)-n'-(4-(7-(2-(morpholin-4-ylethoxy)imidazo(2,1-b) (1,3)benzothiazol-2-yl)phenyl)urea

92. N-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea

93. N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-n'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea

2.4 Create Date
2008-09-08
3 Chemical and Physical Properties
Molecular Weight 560.7 g/mol
Molecular Formula C29H32N6O4S
XLogP35.6
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count8
Exact Mass560.22057470 g/mol
Monoisotopic Mass560.22057470 g/mol
Topological Polar Surface Area134 Ų
Heavy Atom Count40
Formal Charge0
Complexity849
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of acute myeloid leukaemia.


Treatment of acute myeloid leukaemia


5 Pharmacology and Biochemistry
5.1 Pharmacology

In preclinical studies, Quizartinib demonstrated dose-dependent activity and favorable drug-like profiles in bioavailability, pharmacokinetics, cytochrome P450 (CYP) liability, and absorption, distribution, metabolism, excretion (ADME).


5.2 ATC Code

L01XE


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EX - Other protein kinase inhibitors

L01EX11 - Quizartinib


5.3 Mechanism of Action

Quizartinib potently inhibits FLT3, a kinase that is mutated in approximately one-third of acute myeloid leukemia cases, and patients with FLT3 mutations are less responsive to traditional therapies.


Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLee Fine Chem: Advancing Innovation and Quality in Intermediates, APIs, and Dosage Forms for Superior Pharmaceutical Solutions.

Flag India
Digital Content Digital Content

Quizartinib

About the Company : Lee Fine Chem Private Limited specializes in advanced intermediates, Active Pharmaceutical Ingredients (APIs), and finished dosage forms. Focused on quality and innovation, we deli...

Lee Fine Chem Private Limited specializes in advanced intermediates, Active Pharmaceutical Ingredients (APIs), and finished dosage forms. Focused on quality and innovation, we deliver reliable pharmaceutical solutions to global markets. Our state-of-the-art facilities and experienced team ensure regulatory compliance, consistency, and excellence across development and production. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Company Banner

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Quizartinib HCl

About the Company : Daishang Chemical Co., Ltd. established in January 2005, sticking to the guiding principle "Technical innovation, Quality Orientation", we practice best of technology innovation, o...

Daishang Chemical Co., Ltd. established in January 2005, sticking to the guiding principle "Technical innovation, Quality Orientation", we practice best of technology innovation, optimized management and robust service system for our customers. Daishang Chem is specialized in the researching, manufacturing, sales and marketing of API & Its Intermediates as well as other Fine Chemicals, taking great advantages of professional and proficient staff, based on three chemical manufacturing sites and one GMP manufacturing workshops in Liaoning, Henan and Zhejiang provinces, and one R&D laboratory in Zhangjiang Hi-tech Park.
blank

03

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Quizartinib

About the Company : Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing p...

Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing patients across geographies and bridging the gap of unmet needs of medical fraternity through continuous innovation. Our basic business philosophy, by its very nature, serves a social responsibility hence we have a far better reason than profits alone to drive our performance. Sustainability, is not a trend we blindly follow, it is intrinsic to how we have operated since the genesis of the organization in the year 1986.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.


Lead Product(s): Quizartinib,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 13, 2025

blank

01

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 13, 2025

blank

Details:

Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Quizartinib,Inapplicable

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 13, 2025

blank

02

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 13, 2025

blank

Details:

Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.


Lead Product(s): Quizartinib,Inapplicable

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 18, 2024

blank

03

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 18, 2024

blank

Details:

Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Quizartinib,Rufinamide

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 18, 2024

blank

04

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 18, 2024

blank

Details:

VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.


Lead Product(s): Quizartinib,Cytarabine,Daunorubicin

Therapeutic Area: Oncology Brand Name: Vanflyta

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 10, 2024

blank

05

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.

Product Name : Vanflyta

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 10, 2024

blank

Details:

Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia.


Lead Product(s): Quizartinib,Daunorubicin,Idarubicin Hydrochloride,Cytarabine

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 29, 2024

blank

06

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 29, 2024

blank
  • Development Update

Details:

Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.


Lead Product(s): Quizartinib,Etoposide,Dexrazoxane,Mitoxantrone,Cytarabine,Methotrexate,Daunorubicin,Fludarabine Phosphate

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Daiichi Sankyo

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 16, 2024

blank

07

Princess Maxima Center for Pediatric Oncology

Country
arrow
BIO Partnering at JPM
Not Confirmed

Princess Maxima Center for Pediatric Oncology

Country
arrow
BIO Partnering at JPM
Not Confirmed

Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 16, 2024

blank

Details:

VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.


Lead Product(s): Quizartinib,Cytarabine,Daunorubicin

Therapeutic Area: Oncology Brand Name: Vanflyta

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 09, 2023

blank

08

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.

Product Name : Vanflyta

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 09, 2023

blank

Details:

Vanflyta (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.


Lead Product(s): Quizartinib,Cytarabine,Daunorubicin

Therapeutic Area: Oncology Brand Name: Vanflyta

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 15, 2023

blank

09

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Vanflyta (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.

Product Name : Vanflyta

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 15, 2023

blank

Details:

VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.


Lead Product(s): Quizartinib,Cytarabine,Daunorubicin

Therapeutic Area: Oncology Brand Name: Vanflyta

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 09, 2023

blank

10

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.

Product Name : Vanflyta

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 09, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 950769-58-1 / Quizartinib API manufacturers, exporters & distributors?

Quizartinib manufacturers, exporters & distributors 1

67

PharmaCompass offers a list of Quizartinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Quizartinib manufacturer or Quizartinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Quizartinib manufacturer or Quizartinib supplier.

PharmaCompass also assists you with knowing the Quizartinib API Price utilized in the formulation of products. Quizartinib API Price is not always fixed or binding as the Quizartinib Price is obtained through a variety of data sources. The Quizartinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Quizartinib

Synonyms

950769-58-1, Ac220, Quizartinib (ac220), Ac-220, Ac 220, Quizartinib hcl

Cas Number

950769-58-1

Unique Ingredient Identifier (UNII)

7LA4O6Q0D3

About Quizartinib

Quizartinib is an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.

Quizartinib Manufacturers

A Quizartinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Quizartinib, including repackagers and relabelers. The FDA regulates Quizartinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Quizartinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Quizartinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Quizartinib Suppliers

A Quizartinib supplier is an individual or a company that provides Quizartinib active pharmaceutical ingredient (API) or Quizartinib finished formulations upon request. The Quizartinib suppliers may include Quizartinib API manufacturers, exporters, distributors and traders.

click here to find a list of Quizartinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Quizartinib GMP

Quizartinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Quizartinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Quizartinib GMP manufacturer or Quizartinib GMP API supplier for your needs.

Quizartinib CoA

A Quizartinib CoA (Certificate of Analysis) is a formal document that attests to Quizartinib's compliance with Quizartinib specifications and serves as a tool for batch-level quality control.

Quizartinib CoA mostly includes findings from lab analyses of a specific batch. For each Quizartinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Quizartinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Quizartinib EP), Quizartinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Quizartinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty